Phase I, First-in-man, Randomised, Placebo-controlled, Single Dose Escalation Study to Investigate the Effects of LPH-5 on Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Parameters in Healthy Participants
Latest Information Update: 15 Sep 2026
At a glance
- Drugs LPH 5 (Primary)
- Indications Depression; Major depressive disorder
- Focus Adverse reactions; First in man
- Sponsors Lophora
Most Recent Events
- 23 Dec 2025 Status changed from recruiting to completed.
- 12 Dec 2024 New trial record